At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 9 enrolled
Drug / intervention
florbetapir F 18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Positron Emission Tomography Whole Body Biodistribution Using 18F-AV-45
In Brief
A Phase 1 clinical trial evaluating florbetapir F 18 for Alzheimer Disease. Completed, enrolled 9 participants across 1 site.
Detailed Summary
This study will determine how florbetapir F 18 (18F-AV-45) radioactivity is distributed throughout the body.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
Primary CompletionJan 2008
First PostedMar 2012
TodayJul 2026
First PostedMar 28, 2012
Enrollment StartOct 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.3 years ago
Interventions
florbetapir F 18drug
IV injection, 370MBq (10mCi), single dose